Corbus Pharmaceutical Holdings, Inc. (CRBP)

[jeffshir]

News out

07:11 AM EST, 12/17/2018 (MT Newswires) -- Corbus Pharmaceuticals Holdings (CRBP) has started a phase 3 trial to evaluate the efficacy and safety of its investigational drug lenabasum to treat dermatomyositis, or DM, a rare multisystem inflammatory autoimmune disease.

"If the efficacy data from this single phase 3 study are positive, and the safety profile continues to be favorable, we intend to approach regulatory authorities about a registration package for lenabasum for treatment of DM," said Chief Medical Officer Barbara White in a statement.